Loading...
•
Dec 31, 2021
Surmodics Q1 2022 Earnings Report
Surmodics reported a revenue increase of 3% year-over-year, with a GAAP EPS of $(0.20) and a non-GAAP EPS of $(0.13).
Key Takeaways
Surmodics, Inc. announced its first quarter fiscal 2022 results, showing a 3% increase in revenue compared to the prior-year period. The company's GAAP EPS was $(0.20), while non-GAAP EPS was $(0.13). Surmodics also saw the first commercial sale of its Pounce™ Arterial Thrombo-embolectomy System.
Revenue increased by 3% year-over-year, reaching $23.0 million.
GAAP EPS was $(0.20), and non-GAAP EPS was $(0.13).
First commercial sale of the Pounce™ Arterial Thrombo-embolectomy System occurred.
Progress was made on the SurVeil™ drug-coated balloon PMA submission.
Revenue by Segment
Forward Guidance
Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...